Edward Yin-Shiang Lin

This inventor holds 22 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 13 EPO patents, primarily in Sphingosine Modulation. Top assignees: Biogen Ma Inc., Biogen Idec Ma Inc., Sunesis Pharmaceuticals, Inc.. Active years: 2012-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Edward Yin-Shiang Lin. Retrieved from https://idiyas.com/inventor/edward-yin-shiang-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 10)

% Patents Active = 81.8

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 13 (Patent Applications = 16)

Average Co-Inventor Count = 9.9

ph-index = 5

Forward Citations = 95(Granted Patents)

Location History:

Cambridge, MA (US) (2017)
Chestnut Hill, MA (US) (2012 - 2018)
Ashland, MA (US) (2015 - 2021)

Company Filing History:

Sunesis Pharmaceuticals, Inc.

patents

4. 2 out of 855

Millennium Pharmaceuticals Limited

Millenium Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

Areas of Expertise:

NRF2 Activator

S1P Modulating Agents

Heterobicyclic Compounds

PDK1 Inhibitors

Bicyclic Aryl Analog

Sphingosine Analog

Heterobicyclic Sphingosine

Pyridinonyl Compounds

Drug Development

Therapeutic Agents

Chemical Modulators

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10968181 - NRF2 activator (2021-04-06),

2. 10894040 - S1P modulating agents (2021-01-19),

3. 10406144 - SIP modulating agents (2019-09-10),

4. 10166250 - Bicyclic aryl sphingosine 1-phosphate analogs (2019-01-01),

5. 10081646 - Heterobicyclic sphingosine 1-phosphate analogs (2018-09-25),

6. 10034869 - S1P modulating agents (2018-07-31),

7. 10030016 - Heterocyclic compounds useful as PDK1 inhibitors (2018-07-24),

8. 9873693 - Methods of treatment using pyridinonyl PDK1 inhibitors (2018-01-23),

9. 9850206 - S1P and/or ATX modulating agents (2017-12-26),

10. 9827258 - Bicyclic aryl sphingosine 1-phosphate analogs (2017-11-28),

11. 9808449 - S1P modulating agents (2017-11-07),

12. 9708353 - Heterobicyclic sphingosine 1-phosphate analogs (2017-07-18),

13. 9572824 - Bicyclic aryl sphingosine 1-phosphate analogs (2017-02-21),

14. 9546165 - Heterocyclic compounds useful as PDK1 inhibitors (2017-01-17),

15. 9340527 - S1P modulating agents (2016-05-17),

Title: Edward Yin-Shiang Lin: A Pioneer in Pharmaceutical Innovations

Introduction

Edward Yin-Shiang Lin, based in Ashland, MA, is a distinguished inventor with a remarkable portfolio of 22 patents. His innovative contributions primarily focus on pharmaceuticals, aiming to enhance health and treatment options for various medical conditions.

Latest Patents

Among his latest patents, Lin has developed an NRF2 activator, which provides compounds of Formula I and pharmaceutically acceptable salts along with methods for their use and production. Additionally, he is credited with creating S1P modulating agents, which include compounds of formula (I) or (II) and their use in modulating the activity of S1P receptors. These innovations also encompass pharmaceutical compositions that comprise these compounds combined with acceptable excipients or carriers.

Career Highlights

Lin's career has been marked by significant roles in esteemed companies such as Biogen MA Inc. and Sunesis Pharmaceuticals, Inc. His work in these organizations underscores his commitment to advancing pharmaceutical sciences and developing novel therapies.

Collaborations

Throughout his career, Lin has collaborated with notable colleagues, including Kevin Guckian and Gnanasambandam Kumaravel. These partnerships have contributed to his success and the realization of multiple groundbreaking inventions.

Conclusion

Edward Yin-Shiang Lin represents the spirit of innovation in the pharmaceutical industry. With a strong patent portfolio and collaborations that foster progressive research, he continues to be an influential figure in the field, paving the way for future advancements in medicine.

Profile summary based on public USPTO records.